Remove Drug Delivery Remove Drugs Remove FDA Approval Remove Life Science
article thumbnail

XBB.1.5 Omicron Subvariant + FDA Approves AstraZeneca’s New Asthma Inhaler – Xtalks Life Science Podcast Ep. 93

XTalks

Ayesha also talked about the FDA approval of AstraZeneca’s asthma inhaler Airsupra, the first-in-class drug that contains both a beta agonist and corticosteroid. The inhaler is approved as a rescue medication for adults with asthma to help treat bronchoconstriction and asthma attacks.

article thumbnail

Kyowa Kirin backs €125m life science fund closed by Fountain Healthcare

pharmaphorum

Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – 25% ahead of its target – and says it will pump most of the money into European therapeutics and medical device companies. The third fund is now closed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Authorizes Pfizer COVID-19 Vaccine for Children 5 to 11 + Genentech’s Ocular Implant for Macular Degeneration – Xtalks Life Science Podcast Ep. 35

XTalks

The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Read the full articles here: FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11.

article thumbnail

FDA Approves AbbVie’s Vuity as the First Eyedrop for Presbyopia

XTalks

Now, instead of reaching for reading glasses, AbbVie’s eyedrop formulation Vuity could offer help in correcting far-sightedness as the US Food and Drug Administration (FDA) granted approval to it late last week. With the approval, Vuity becomes the first eyedrop approved for presbyopia. Vuity is a 1.25

article thumbnail

Agent Drug-Coated Balloon: A New Era in Coronary In-Stent Restenosis Treatment

XTalks

The US Food and Drug Administration (FDA) recently approved Boston Scientific’s Agent drug-coated balloon (DCB) for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease (CAD). Repeat PCI: For patients experiencing restenosis, a repeat PCI procedure can be performed.

Drugs 52
article thumbnail

Five key drug discovery deals of summer 2023

Drug Discovery World

The life sciences sector has seen significant M&A activity over the last few weeks. The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.

Drugs 52
article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

percent received approval from the US Food and Drug Administration (FDA) to treat dry eye disease. Attendees will understand best practices for novel drug delivery design and development. Attendees will understand best practices for novel drug delivery design and development. What Is Dry Eye Disease?